<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=405009060588537&amp;ev=PageView&amp;noscript=1">

In this article Macrovue’s investment committee looks at three global companies disrupting their respective industries through technology research and development.

Twilio (NYSE: TWLO)

On 6 May 2019 Twilio announced the launch of “Trust Onboard”, a feature for its “internet of things” (IoT) SIMs that enables developers to identify and authenticate cellular connected devices against cloud services. With Trust Onboard, Twilio now delivers connectivity, device identification and authentication capabilities on a single SIM, dramatically accelerating IoT time to market. At Microsoft Build, Twilio also announced integration with Azure IoT as part of Microsoft's IoT Plug and Play connectivity, allowing IoT developers to sync devices to their Azure cloud from the Twilio Console, establishing trust as soon as the device comes online. This product addresses the problems that developers have when they try to reliably connect large fleets of devices to cellular networks of different types around the world. Twilio's IoT SIMs and Wireless Supernetwork address this issue directly with a simple, secure mechanism to exchange data with their devices particularly as IoT device fleets get larger and time to market becomes more critical. Having Trust Onboard certificates pre-embedded on each SIM reduces the time it takes to get an IoT solution to market while adhering to best practices.


In order to bolster its already strong Merchant Services business, PayPal has announced the start of an e-commerce system that allows small business same access to online shopping infrastructure as the tech giants. “PayPal Commerce Platform” allows merchants to accept money online, and shoppers to check-out through PayPal; also facilitates functions like fraud protection. The platform is already in use by Instagram Checkout and Facebook Marketplace, and is now extended to all sellers and merchants. “Sellers are trying to figure out how they can go compete with the very largest online retailers. This is a huge opportunity for them”, PayPal’s COO Bill Ready recently told CNBC. Product will be available across U.S., U.K. and Europe first; PayPal plans to expand to all other markets where they operate including Australia. 

Illumina (NASDAQ: ILMN)

(Company Release 4 June 2019, verbatim)

Illumina, Inc. today announced the launch of VeriSeq™ NIPT Solution v2, a CE-IVD, next-generation sequencing (NGS)-based approach to noninvasive prenatal testing (NIPT). The automated comprehensive solution allows laboratories to screen for a broader range of chromosomal and sub-chromosomal conditions associated with birth defects and adverse pregnancy outcomes than the standard NIPT menu. VeriSeq NIPT Solution v2 delivers the most comprehensive view of the fetal genome compared to other CE-IVD NIPT products, enabling healthcare providers to support expectant parents with informed, timely and personalized pregnancy management options better than ever before. VeriSeq NIPT Solution v2 is now available across most countries in Europe, as well as South Africa. Product registration is pending in Australia, Israel and New Zealand.

VeriSeq NIPT Solution v2 provides accurate information about fetal chromosomal status as early as 10 weeks of gestation using a single maternal blood draw. This noninvasive test provides an option to screen for aneuploidy in all autosomes, chromosomes X & Y, and partial deletions and duplications greater than 7 Mb across the genome. Due to its high-sensitivity and high-specificity (low false-positive and false-negative rates), NGS-based NIPT minimizes the need for invasive testing procedures. The automated, reliable solution provides reagents, instruments, installation and training, and offers unprecedented turnaround times; laboratories can process up to 96 samples in approximately one day.”

We believe one of the key drivers for Illumina’s growth going forward is the non-invasive prenatal testing or NIPT business. ILMN continues to submit new IVD applications to expand the geographic opportunity for VeriSeq NIPT, while in the U.S., average risk reimbursement coverage stands at just~43% with the anticipated ACOG guideline change expected to drive positive coverage decisions from United and Aetna in the near term.

You can invest in these companies directly through Macrovue's Disruptive Technologies share portfolio.

This portfolio has returned 29.90% over the last 12 months (to 31 May 2019). 

Important: This content has been prepared without taking account of the objectives, financial situation or needs of any particular individual and does not constitute financial advice. Consider the appropriateness of the information in regards to your circumstances.

Past performance is not a reliable indicator of future performance. 

More Posts